कंपनी का अवलोकन
GRI Bio, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to discovering, developing, and commercializing therapeutic interventions for inflammatory, fibrotic, and autoimmune disorders within the United States. The company functions within the broader Healthcare sector, specifically targeting the specialized Biotechnology industry where high-risk research and development activities are paramount for creating novel medical treatments. As of the latest available data, the organization employs a minimal workforce of three individuals and holds a market capitalization of $3.41 million. These valuation and scale metrics indicate that GRI Bio is a micro-cap entity with a very small operational footprint, reflecting the early-stage nature of its development pipeline where significant resources are likely allocated to research rather than commercial sales or large-scale manufacturing operations.
वित्तीय स्वास्थ्य
The company reports a Net Income of $-11,956,000 for the trailing twelve months, while its EBITDA stands at $-11,973,000, and the Trailing Twelve Month revenue figure is listed as N/A. The substantial negative value in Net Income relative to the near-zero revenue suggests an aggressive cost structure driven by extensive research and development expenditures or clinical trial costs that far exceed any current product sales revenue. Free Cash Flow is reported at $-5,468,625, which indicates that the company is burning through its liquid assets to fund its operations and development goals, thereby limiting its immediate financial flexibility without external capital injections. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a figure typical for pre-revenue biotechnology firms where costs are incurred before any commercial revenue is generated to offset them. The balance sheet shows a cash position of $8.23 million against a debt load of only $71,000, resulting in a Debt to Equity ratio of 1.18 which warrants close scrutiny given the negative equity implied by the losses. Despite the high debt-to-equity ratio, the Current Ratio of 3.25 demonstrates that the company possesses ample short-term assets to cover its liabilities, suggesting a conservative liquidity stance relative to its immediate obligations. Return on Equity is -238.2% and Return on Assets is -103.9%, revealing that management's effectiveness in generating profit from the invested capital base is currently negative due to the cumulative losses and the lack of profitable operations to distribute returns to shareholders.
मूल्यांकन आकलन
Trailing P/E Ratio is N/A due to the negative earnings, while the Forward P/E is listed as -0.29, implying that market expectations for future earnings remain highly uncertain or negative in the short term given the company's developmental stage. The Price to Book ratio stands at 0.20, indicating that the stock trades at a significant discount to its book value, a common characteristic for speculative biotech stocks where market sentiment undervalues the intangible research assets. Price to Sales is N/A as there is no revenue data, and the EV/EBITDA ratio is 0.40, suggesting an enterprise valuation based on earnings before interest, taxes, depreciation, and amortization that is mathematically low but skewed by the negative earnings profile. The 52-week price range spans from a low of $2.10 to a high of $80.36, placing the current valuation context within a highly volatile historical band where the stock has experienced substantial price swings. The Beta value of -1.24 is anomalous for equity securities, suggesting a price movement pattern that historically has moved inversely or with extreme volatility relative to the broader market, increasing the risk profile for price-sensitive investors.
Growth & Income
Revenue Growth and Earnings Growth for the year-over-year period are both listed as N/A, preventing a direct comparison of growth rates but highlighting the company's status as a pre-revenue entity with no historical earnings growth trajectory to analyze. The company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, which means all available earnings and cash reserves are retained within the business to fund ongoing research and development efforts rather than being distributed to shareholders. Consequently, the company reinvests its limited financial resources entirely into expanding its clinical pipeline and seeking external financing rather than providing income streams to investors. The overall growth and income profile is characterized by a complete absence of current profitability or dividend income, relying solely on the potential future success of its lead product candidate GRI-0621 to eventually generate revenue and restore positive financial metrics.